Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era  by Ahn, Myung-Ju et al.
ORIGINAL ARTICLE
Korean Ethnicity as Compared with White Ethnicity Is an
Independent Favorable Prognostic Factor for Overall
Survival in Non-small Cell Lung Cancer before and after
the Oral Epidermal Growth Factor Receptor Tyrosine Kinase
Inhibitor Era
Myung-Ju Ahn, MD, PhD,* Jeeyun Lee, MD,* Yun-Hee Park, MD,* Jin-Seok Ahn, MD,*
Argyrios Ziogas, PhD,†‡ Jason A. Zell, DO, MPH,†‡§ Keunchil Park, MD, PhD,*
and Sai-Hong Ignatius Ou, MD, PhD†‡§
Background: We have previously demonstrated, using a regional
California Cancer Registry database, that Asian ethnicity is an
independent favorable prognostic factor for overall survival (OS) in
non-small cell lung cancer (NSCLC).
Methods: Retrospective population-based analysis of Korean and
US white patients with NSCLC with known smoking status from
Samsung Cancer Center, Seoul, South Korea, and a Southern Cal-
ifornia Regional Cancer Registry between 1998 and 2005 with
follow-up through February 2008 to allow for even case ascertain-
ment periods before and after 2002, when epidermal growth factor
receptor tyrosine kinase inhibitors were introduced in Korea and
considered as the year of reference.
Results: A total of 4622 Korean and 8846 US white patients were
analyzed. Median age of diagnosis was 63 years versus 71 years for
Korean and white patients, respectively (P  0.0001). A total of
34.5% of Korean compared with 8.2% white patients were never-
smokers. There was significant OS improvement in never-smokers
when compared with ever-smokers among either Korean patients
(p  0.0141) or US white (p  0.0397), respectively. There was
significant improvement in OS among Korean patients from 2002 to
2005 compared with 1998–2001 (p  0.0001) but not among US
white patients (p  0.5641). Except for stage II patients (p 
0.0723), univariate analysis revealed Korean patients had improved
OS compared with US white patients among stages I, III, and IV,
respectively (all p  0.0001). Multivariate analysis revealed Korean
ethnicity (versus white; hazard ratio (HR) 0.869; p 0.0001) was
an independent favorable factor for OS. The adjusted HR for OS
Korean ethnicity when compared with white ethnicity improved
during 2002–2005 (HR  0.795; p  0.0001) compared with
1998–2001 (HR  0.889; p  0.0013).
Conclusions: These results suggest that Korean ethnicity compared
with US white ethnicity is an independent favorable prognostic
factor for OS in NSCLC. In addition, greater survival benefit among
Korean patients with NSCLC was noted in the postepidermal growth
factor receptor tyrosine kinase inhibitor era (2002 and after) com-
pared with US white ethnicity.
Key Words: Korean ethnicity, White ethnicity, Prognostic factors,
Non-small cell lung cancer, California Cancer Registry, Epidemiol-
ogy, Smoking status, Never-smokers.
(J Thorac Oncol. 2010;5: 1185–1196)
The majority of lung cancer is caused by tobacco expo-sure.1 In addition, globally lung cancer in never-smokers
accounts for the seventh leading cause of cancer death.2 The
approval of epidermal growth factor receptor (EGFR) ty-
rosine kinase inhibitors (TKIs), the discovery of activating
mutations in EGFR, and epidemiologic studies have led to the
recognition that lung cancer in never-smokers represents a
distinct clinical entity.3 Never-smokers with non-small cell
lung cancer (NSCLC) are more likely to have the following
characteristics: female gender, Asian ethnicity, adenocarci-
noma histology, tumors with activating EGFR mutations, and
improved survival. The introduction of oral EGFR TKIs such
as gefitinib and erlotinib led to significant improvement in
overall survival (OS) of patients in Japan4 and Korea5 and
ushered in the EGFR TKI era in NSCLC.
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Using a regional California Cancer Registry (CCR)
database, we have previously shown that Asian ethnicity is an
independent favorable prognostic factor for OS in NSCLC
after adjustment for smoking status and other relevant clinical
variables.6 The number of Asian patients in that study con-
stituted only 6.5% of the total population, and, additionally,
Asian patients represented a diverse subgroup of patients. In
this study, we wanted to extend this observation by perform-
ing a combined analysis of patients with NSCLC from the
cancer registry at Samsung Medical Center in Seoul, South
Korea, and the previously reported regional CCR. Further-
more, we also wanted to analyze any potential difference in
survival outcome before and after the introduction of oral
EGFR TKI in Asia versus the US in 2002.
PATIENTS AND METHODS
This was a retrospective study involving analysis of
NSCLC from the Cancer Surveillance Programs of Orange,
Imperial, and San Diego counties (CSPOC/SANDIOCC da-
tabases) in the state of California, United States of America,
and the Samsung Medical Center Cancer Registry in Seoul,
South Korea.
Patients with NSCLC diagnosed between 1998 and
2005 with complete follow-up data were included in the
analysis. Tumor site and histology were abstracted using
ICD-O-3 codes as previously described.6,7 The histology
category of mixed/carcinoma not otherwise specified (NOS)/
other was obtained by examining histologic codes that did not
further classify NSCLC into adenocarcinoma, squamous cell,
large cell, or bronchioloalveolar carcinoma (BAC).8 Ameri-
can Joint Committee on Cancer (AJCC) stages were deter-
mined from programming according to the sixth edition
AJCC staging system using available clinical and pathologic
tumor, node, metastasis (TNM) data from the cancer registry.
We analyzed eight clinicopathologic variables common
to both registries: age, gender, histology, AJCC stage, period
of diagnosis, surgery, radiation, and chemotherapy. The en-
tire study period was evenly divided into two periods of
diagnosis (period 1: 1989–2001 and period 2: 2002–2005).
Smoking status in California was abstracted by examining
individual patient text file using a text-mining program.6,7
Patient with any documented history of smoking was classi-
fied as “ever-smoker.” Patient with documentation of no
smoking history was classified as “never-smoker.” The last
date of follow-up was February, 29, 2008.
Statistical Analyses
Comparisons of demographic, clinical, and pathologic
variables were made for patients with NSCLC, using Pear-
son’s 2 statistic or Fisher’s exact test for nominal variables
and Student’s t test for continuous variables. Comparison of
nonparametric values across two groups were done using
Wilcoxon rank sum test. Univariate survival rate analyses
were estimated using the Kaplan and Meier method, with
comparisons made between groups by the log-rank test. Cox
proportional hazards modeling using time since diagnosis
were performed. All statistical analyses were conducted using
SAS 9.2 statistical software (SAS Institute, Inc., Cary, NC).
Statistical significance was assumed for a two-tailed p value
0.05.
Ethical Considerations
This research study was approved by the University
of California Irvine Institutional Review Board (IRB) (IRB
#2007–6078) and by the IRB of the Samsung Medical
Center.
RESULTS
Patient Characteristics by Period of Diagnosis
A total of 13,468 patients with NSCLC including 4622
Korean (34.3%) and 8846 white (65.7%) patients were ana-
lyzed. The median age of Korean patients was 63 years
compared with 71 years for white (p  0.0001). A total of
34.5% of Korean compared with 8.2% white patients were
never-smokers (p  0.0001). The proportion of both Korean
and US white patients who were never-smokers had increased
from the pre-EGFR TKI to the post-EGFR TKI era. The
proportion of females among white patients with NSCLC
(47.8%) who were female were greater than Korean patients
with NSCLC (25.5%; p  0.0001). A total of 18.5% of the
white compared with only 2.7% of the Korean patients were
in the “very elderly” age category (80 years or older). Ade-
nocarcinoma was the most common histology overall followed
by squamous cell carcinoma and undifferentiated/mixed/
NOS. Adenocarcinoma was the most common histology
among both Korean (47.1%) and white (42.0%) patients.
The complete clinicopathologic characteristics of Korean
and white patients overall and according to period of
diagnosis are listed in Table 1.
Patient Characteristics by Gender
Female Korean patients with NSCLC were signifi-
cantly younger than male Korean patients (median age: 60
years versus 63 years; p  0.0001 by Wilcoxon rank sum
test). Conversely, female white patients were significantly
older than male white patients (median age: 72 years versus
70 years; p  0.0001 by Wilcoxon rank sum test). Most of
female Korean patients were never-smokers (89.1%),
whereas only 10.8% of female white patients were never-
smokers. The proportion of never-smokers among Korean
males (15.8%) was also higher than white males (5.8%)
(Table 2). The majority of female Korean patient presented
with adenocarcinoma (72.6%) compared with only 38.4% of
male Korean patients (p  0.0001). Female white patients
also presented with a higher proportion of adenocarcinoma
than male white patients (46.1% versus 38.3%; p  0.0001)
(Table 3).
Patient Characteristics by Smoking Status
Korean never-smokers were significantly younger than
Korean ever-smokers (median age: 61 years versus 63 years;
p  0.0001 by Wilcoxon rank sum test). Conversely, white
never-smokers were significantly older than white ever-
smokers (median age: 75 years versus 70 years; p  0.0001
by Wilcoxon rank sum test). Only 4.3% of Korean ever-
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smokers were females, when compared with 65.9% of Ko-
rean never-smokers were females.
Patient Characteristics by Smoking Status and
Gender
The median age of white patients was significantly higher
than Korean patients independent of smoking status or gender.
The most common histology among Korean ever-smokers was
squamous cell carcinoma (48.1%), whereas adenocarcinoma
was the most common histology (41.3%) among white ever-
smokers. Overall, Korean ever-smokers presented with a higher
proportion of squamous cell carcinoma than white ever-smokers
overall (48.1% versus 21.4%), and among male (48.8% versus
25.1%) and female ever-smokers (32.6% versus 17.2%). In
addition, a higher proportion of male Korean never-smokers
developed squamous cell carcinoma than male white never-
smokers (20.1% versus 12.3%). On the other hand, the propor-
tion of squamous cell carcinoma among both Korean and white
female never-smokers was low (6.8 and 7.7%, respectively).
The comparisons of the clinicopathologic characteristics be-
tween Korean and white patients stratified by smoking status and
gender are listed in Table 3.
Univariate Survival Analysis
Individual Clinicopathologic Variable
Never-smokers had significantly improved OSwhen com-
pared with ever-smokers for both Korean (p  0.0141) and
white patients (p 0.0397). Similarly, females had significantly
improved OS when compared with male patients for both
Korean (p  0.0001) and white (p  0.0001). However, while
OS of Korean patients had improved significantly from period 1
to period 2 (p 0.0001), the OS of white patients remained the
same during the two periods (p  0.5641) (Table 4).
Pairwise Comparisons of Individual
Clinicopathologic Variable by Ethnicity
Pairwise comparisons of OS between Korean and white
patients according to individual clinicopathologic variable were
performed, and the unadjusted hazard ratio (HR) are listed in
Table 5. With the exception of patients with stage II or unknown
AJCC stage or patients 80 years or older, all the unadjusted HRs
were statistically improved in Korean patients when compared
with white patients (Table 5). OS of Korean and white patientsTA
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TABLE 2. Comparison of Korean and White Patients by
Smoking Status According to Gender
Korean White p
Male
N 3442 4618
Smoking status 0.0001
Never-smoker (%) 15.8% 5.8%
Ever-smoker (%) 84.2% 94.2%
Female
N 1180 4228
Smoking status 0.0001
Never-smoker (%) 89.1% 10.8%
Ever-smoker (%) 10.9% 89.2%
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according to AJCC stages I, II, III, and IV were plotted in
Figures 1A–D, respectively.
We then performed the same pairwise comparisons ac-
cording to the two periods of diagnosis. The OS of Korean
patients was statistically significantly improved over white pa-
tients in both periods (Tables 5 and 6) as were Korean ever-
smokers when compared with white ever-smokers. Although
there was no statistically significant difference in OS between
Korean and white never-smokers in period 1 (1998–2001), the
survival of Korean never-smokers was significantly improved
over white never-smokers in period 2 (2002–2005) (Table 6). In
addition, more pairwise comparisons revealed significantly im-
proved OS of Korean patients compared with white patients in
period 2 than in period 1 (Table 6). Finally, we performed
pairwise comparisons on the differences in OS of individual
clinicopathologic variable according to the two periods of diag-
nosis among Korean (Supplemental Table 1, http://links.lww.
com/JTO/A30) and white (Supplemental Table 2, http://links.
lww. com/JTO/A29) patients (Figure 2, A and B, respectively).
Multivariate Analysis
We performed Cox proportional hazards analysis to
identify independent prognostic factors for OS. After ac-
counting for age, gender, smoking status, histology, period of
diagnosis, AJCC stage, surgery, radiation, and chemotherapy,
Korean ethnicity remained an independent favorable prog-
TABLE 4. Univariate Analysis of Survival of Korean and US Patients
Korean (N  4622) US (N  8846)
Median
OS (mo)
2-yr Survival
Estimates (%) p
Median
OS (mo)
2-yr Survival
Estimate (%) p
Smoking status 0.0141 0.0397
Ever-smoker (N  3028) 14 36.5 Ever-smoker (N  8121) 9 28.4
Never-smoker (N  1594) 18 41.8 Never-smoker (N  725) 11 30.7
Gender 0.0001 0.0001
Male (N  3442) 14 35.9 Male (N  4618) 8 24.8
Female (N  1180) 20 45.6 0.0001 Female (N  4228) 10 32.7
Age category 0.0001 0.0001
0–39 (N  167) 21 40.7 0–39 (N  45) 11 31.4
40–49 (N  477) 21 43.7 40–49 (N  359) 12 30.6
50–59 (N  1081) 21 43.6 50–59 (N  1209) 10 32.7
60–69 (N  1863) 15 36.0 60–69 (N  2457) 12 34.3
70–79 (N  908) 11 28.5 70–79 (N  3142) 9 27.5
80 (N  126) 8.5 18.4 80 (N  1634) 5 18.6
Histology 0.0001 0.0001
AdenoCA (N  2177) 16 39.0 AdenoCA (N  3716) 11 33.8
BAC (N  131) NR 77.1 BAC (N  364) 56 64.6
SqCC (N  1637) 18 41.2 SqCC (N  1809) 11 31.2
Large Cell (N  91) 15 39.6 Large Cell (N  444) 6 23.0
NOS (N  586) 8 19.1 NOS (N  2513) 5 14.9
AJCC stage 0.0001 0.0001
I (N  1034) 100 82.5 I (N  1264) 63 72.8
II (N  335) 41 65.1 II (N  330) 33 56.9
III (N  1323) 14 33.0 III (N  1487) 10 24.3
IV (N  1916) 7 13.7 IV (N  4309) 5 12.6
Unknown (N  13) 10 23.1 Unknown (N  1456) 13 35.7
Period of diagnosis 0.0001 0.5641
1998–2001 (N  1898) 12 31.8 1998–2001 (N  4698) 9 27.8
2002–2005 (N  2724) 18 43.0 2002–2005 (N  4148) 9 29.6
Surgery 0.0001 0.0001
Yes (N  1897) 62 69.0 Yes (N  2590) 51 67.6
No (n  2725) 9 17.1 No (n  6251) 5 12.4
Radiation 0.0001 0.0001
Yes (N  1713) 14 32.1 Yes (N  3461) 9 20.7
No (N  2909) 17 42.0 No (N  5383) 10 33.8
Chemotherapy 0.0369 0.3503
Yes (N  1566) 18 37.7 Yes (N  3035) 11 24.8
No (N  3056) 14 38.7 No (N  5791) 7 30.6
Unknown (N  0) — — Unknown (N  20) 6.5 15.0
AdenoCA, adenocarcinoma; BAC, bronchioloalveolar carcinoma; SqCC, squamous cell carcinoma; NOS, not otherwise specified; AJCC, American Joint Committee on Cancer;
NR, not reached.
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nostic factor for OS (versus white; HR  0.869, 95% confi-
dence interval (CI) 0.826–0.913, p 0.0001) (Table 7). In
addition, among adenocarcinoma patients (Korean versus
white; HR  0.886; 95% CI: 0.82–0.955; p  0.0016) and
squamous cell carcinoma patients (Korean versus white;
HR  0.852; 95% CI: 0.776–0.935; p  0.0006), Korean
ethnicity was an independent favorable prognostic factor for
OS. Other favorable prognostic factors for OS identified
included younger age, female gender, BAC, early stage, more
recent period of diagnosis, and treatment received. Within
individual period of diagnosis, Korean ethnicity remained an
independent favorable prognostic factor in both period 1
(versus white; HR  0.909; 95% CI: 0.848–0.975, p 
0.0001) and in period 2 (versus white; HR  0.824; 95% CI:
0.766–0.887, p  0.0001).
DISCUSSION
In this study, we compared and contrasted the clinico-
pathologic characteristics and survival outcome of Korean
and white patients to further investigate whether Asian eth-
nicity is an independent favorable prognostic factor in
NSCLC. Korean never-smokers were significantly younger
than Korean ever-smokers (61 years versus 63 years; p 
0.0001), whereas white never-smokers were significantly
older than white ever-smokers (75 years versus 70 years; p 
TABLE 5. Comparison of Survival between Korean and US Patients by Individual
Clinicopathologic Category All Period
US Median
OS (mo)
Korean Median
OS (mo)
Unadjusted HR
(95% CI) p
Overall 9 (9–10) 16 (15–16) 0.738 (0.709–0.763) 0.0001
Smoking status
Ever-smoker 9 (8–9) 14 (13–15) 0.755 (0.720–0.791) 0.0001
Never-smoker 11 (9–13) 18 (16–20) 0.754 (0.682–0.833) 0.0001
Gender
Male 8 (2–27) 14 (13–15) 0.695 (0.662–0.731) 0.0001
Female 10 (10–11) 20 (18–23) 0.729 (0.676–0.786) 0.0001
Age category
0–39 11 (8–24) 21 (16–26) 0.645 (0.441–0.945) 0.0245
40–49 12 (10–13) 21 (18–25) 0.696 (0.593–0.816) 0.0001
50–59 10 (9–12) 21 (19–23) 0.718 (0.652–0.790) 0.0001
60–69 12 (11–13) 15 (14–16) 0.880 (0.822–0.942) 0.0002
70–79 9 (8–9) 11 (9–12) 0.910 (0.840–0.987) 0.0255
80 5 (4–5) 8.5 (7–11) 0.842 (0.695–1.020) 0.0783
Period of diagnosis
1998–2001 9 (8–9) 12 (11–13) 0.840 (0.793–0.890) 0.0001
2002–2005 9 (9–10) 18 (17–20) 0.661 (0.625–0.701) 0.0001
Histology
AdenoCA 11 (10–12) 16 (15–17) 0.872 (0.821–0.926) 0.0001
BAC 56 (43–68) NR (99–NR) 0.540 (0.383–0.760) 0.0004
SqCC 11 (10–12) 18 (16–19) 0.714 (0.662–0.771) 0.0001
Large Cell 6 (5–7) 15 (10–23) 0.510 (0.388–0.670) 0.0001
Undifferentiated/NOS 5 (5–6) 8 (7–9) 0.775 (0.704–0.852) 0.0001
AJCC stage
I 63 (58–69) 100 (89–125) 0.618 (0.543–0.705) 0.0001
II 33 (27–38) 41 (35–49) 0.836 (0.687–1.016) 0.0723
III 10 (9–11) 14 (12–15) 0.772 (0.712–0.836) 0.0001
IV 5 (4–5) 7 (7–8) 0.846 (0.800–0.894) 0.0001
Unknown 13 (12–14) 10 (1–22) 1.420 (0.822–2.451) 0.2086
Surgery
Yes 51 (47–54) 62 (57–70) 0.865 (0.797–0.940) 0.0006
No 5 (5–6) 9 (8–9) 0.787 (0.751–0.824) 0.0001
Radiation
Yes 9 (8–9) 14 (12–15) 0.746 (0.701–0.794) 0.0001
No 10 (9–10) 17 (16–18) 0.731 (0.694–0.771) 0.0001
Chemotherapy
Yes 11 (11–12) 18 (16–19) 0.729 (0.681–0.780) 0.0001
No 7 (7–8) 14 (12–15) 0.732 (0.696–0.770) 0.0001
OS, overall survival; HR, hazard ratio; CI, confidence interval; AdenoCA, adenocarcinoma; BAC, bronchioloalveolar
carcinoma; SqCC, squamous cell carcinoma; NOS, not otherwise specified; AJCC, American Joint Committee on Cancer; NR,
not reached.
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0.0001). Epidemiologic analyses of white patients with
NSCLC in the United States have consistently found that
never-smokers are significantly older than ever-smokers.6,9
Difference in the median age of diagnosis may point to a
difference in etiology and pathogenesis of NSCLC. There-
fore, there may not only be a difference in the etiology and
pathogenesis of NSCLC among never-smokers and ever-
smokers in both Korea and United States but also a difference
in etiology and pathogenesis of NSCLC between Korean and
US white never-smokers. The many potential causes of
NSCLC in never-smokers have been reviewed recently.10
We identified significant differences in the distribution
of NSCLC tumor histology between Korean and white ever-
smokers. Squamous cell carcinoma was the most common
histology (48.1%) among Koreans ever-smokers, whereas
adenocarcinoma (41.3%) was the most common histology
among whites ever-smokers. One potential explanation for
this difference may be attributed to the length of tobacco
exposure. Squamous cell carcinoma is more commonly found
in patients with NSCLC who continue to smoke tobacco,11
whereas adenocarcinoma is more commonly found in former
smokers as smoking cessation resulted in the sharpest decline
in both small cell and squamous cell carcinoma.12 It is
conceivable that there are more former smokers among
whites than among Koreans, or the earlier introduction of
filtered cigarettes in the US market may have contributed to
the differences in the observed histologic difference among
ever-smokers.
Although female patients comprised the majority of
never-smokers among both Koreans and US whites, only
4.3% of Korean ever-smokers were females compared with
46.5% of white females. Furthermore, 89.1% of the Korean
female patients with NSCLC were never-smokers compared
with only 10.8% of white female patients with NSCLC were
never-smokers. Korean female patients were younger than
Korean male patients (60 years versus 63 years; p  0.0001),
whereas white female patients were older than white male
patients (72 years versus 70 years; p  0.0001). Of note, a
FIGURE 1. A, Kaplan-Meier survival curves of stage I patients with NSCLC. B, Kaplan-Meier survival curves of stage II patients
with NSCLC. C, Kaplan-Meier survival curves of stage III patients with NSCLC. D, Kaplan-Meier survival curves of stage IV pa-
tients with NSCLC. NSCLC, non-small cell lung cancer.
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meta-analysis of 55 studies of passive smoking and lung
cancer reported that Asia and European woman seemed to
have higher relative risk of developing lung cancer than
North American women.13
In this observational analysis of NSCLC data, survival
of Korean patients had significantly improved from the pre-
EGFR TKI period (1998–2001) to the post-EGFR TKI period
(2002–2005), whereas the survival of white patients had not.
Kim et al.5 reported that there was a 7.8 months of improve-
ment in OS in Korean patients who received gefitinib during
the period 2002–2005 compared with those who did not
receive gefitinib during the period from 1999 to 2001. Similar
to Korea where the first oral EGFR TKI, gefitinib, was
introduced as part of expanded access program in 2002 and
approved in June 2003, gefitinib was approved in the United
States in May 5, 2003, for third-line treatment of NSCLC.14
Subsequently, erlotinib was approved in November 18, 2004,
in the United States for both second- and third-line treatment
of NSCLC.15 The lack of survival improvement in whites
observed in this study between 2002 and 2005 during which
EGFR TKIs have been approved for use in the United States
when compared with period between 1998 and 2001 may be
due to the later introduction of oral EGFR TKIs (2003 in
United States versus 2002 in Korea), lower efficacy of oral
EGFR TKIs in white patients when compared with Asians,16
or EGFR TKIs being used as a later line of treatment in the
United States (third-line) than in Korea (second-line). How-
ever, we could not ascertain the use of EGFR TKIs from the
CCR nor the line of therapy they were being used. Neverthe-
less, the higher proportion of never-smokers17 and activating
TABLE 6. Comparison of Survival between Korean and US Patients by Individual Clinicopathologic Category Diagnosed from
1998 to 2001 and 2002 to 2005
1998–2001 2002–2005
US Median
OS (mo)
(95% CI)
Korean Median
OS (mo)
(95% CI)
Unadjusted HR
(95% CI) p
US Median
OS (mo)
(95% CI)
Korean Median
OS (mo)
(95% CI)
Unadjusted HR
(95% CI) p
All patients 9 (8–9) 12 (11–13) 0.840 (0.793–0.890) 0.0001 9 (9–10) `18 (17–20) 0.661 (0.625–0.701) 0.0001
Smoking status
Ever-smoker 9 (8–9) 12 (10–13) 0.837 (0.783–0.894) 0.0001 9 (9–10) 17 (15–18) 0.686 (0.641–0.734) 0.0001
Never-smoker 11 (8–13) 12 (11–15) 0.913 (0.791–1.055) 0.2187 12 (9–14) 22 (19–24) 0.646 (0.561–0.744) 0.0001
Gender
Male 8 (7–9) 11 (10–12) 0.793 (0.740–0.853) 0.0001 8 (7–9) 16 (15–18) 0.617 (0.575–0.663) 0.0001
Female 10 (9–11) 14 (12–16) 0.844 (0.755–0.943) 0.0028 11 (10–12) 25 (22–28) 0.652 (0.588–0.723) 0.0001
Age category
0–39 8 (5–19) 18 (7–26) 0.576 (0.347–0.958) 0.0334 15 (8–NR) 22 (17–34) 0.824 (0.453–1.500) 0.5263
40–49 12 (10–15) 16 (12–20) 0.858 (0.687–1.072) 0.1771 11 (8–14) 25 (21–30) 0.567 (0.448–0.718) 0.0001
50–59 11 (9–13) 15 (12–18) 0.879 (0.769–1.005) 0.0587 10 (9–13) 26 (23–30) 0.590 (0.513–0.679) 0.0001
60–69 11 (10–13) 12 (10–14) 0.973 (0.884–1.071) 0.5812 12 (10–13) 18 (16–19) 0.798 (0.722–0.882) 0.0001
70–79 8 (7–9) 8.5 (7–10) 1.031 (0.918–1.157) 0.6066 10 (9–11) 12 (11–15) 0.836 (0.746–0.938) 0.0022
80 5 (4–5) 10 (4–14) 0.833 (0.601–1.154) 0.2712 5 (5–7) 8 (6–11) 0.857 (0.676–1.087) 0.2033
Histology
AdenoCA 11 (10–12) 11 (10–12) 1.010 (0.928–1.099) 0.8169 12 (10–13) 20 (18–23) 0.778 (0.714–0.849) 0.0001
BAC 58 (39–76) 99 (15–NR) 0.773 (0.491–1.217) 0.2663 50 (34–69) NR (NR–NR) 0.367 (0.215–0.625) 0.0002
SqCC 11 (10–12) 15 (13–17) 0.795 (0.716–0.883) 0.0001 12 (10–13) 21 (18–23) 0.640 (0.571–0.718) 0.0001
Large Cell 6 (4–7) 17 (9–94) 0.442 (0.279–0.700) 0.0005 8 (6–10) 14.5 (9–26) 0.570 (0.402–0.809) 0.0016
Undifferentiated/NOS 5 (5–6) 7 (6–8) 0.903 (0.775–1.053) 0.1929 5 (5–6) 9 (8–10) 0.719 (0.635–0.813) 0.0001
AJCC stage
I 64 (56–71) 100 (89–125) 0.623 (0.520–0.747) 0.0001 58 (52–62) 75 (NR–NR) 0.592 (0.483–0.725) 0.0001
II 30 (24–38) 25 (21–36) 1.162 (0.896–1.508) 0.2584 34 (22–53) 50 (40–NR) 0.648 (0.466–0.900) 0.0096
III 10 (9–11) 12 (11–14) 0.831 (0.743–0.928) 0.0011 10 (9–12) 15 (14–17) 0.724 (0.643–0.817) 0.0001
IV 4 (4–5) 6 (6–7) 0.905 (0.835–0.981) 0.0149 5 (5–6) 9 (8–9) 0.804 (0.745–0.868) 0.0001
Unknown 12 (11–13) 9 (1–18) 1.502 (0.828–2.726) 0.1808 16 (13–19) 31 (22–40) 0.990 (0.247–3.970) 0.9882
Surgery
Yes 48 (44–54) 52 (41–62) 0.898 (0.800–1.008) 0.0689 51 (46–54) 66 (58–75) 0.852 (0.751–0.966) 0.0125
No 5 (0–NR) 8 (7–8) 0.863 (0.807–0.922) 0.0001 5 (5–6) 10 (9–10) 0.727 (0.681–0.776) 0.0001
Radiation
Yes 8 (8–9) 11 (10–12) 0.835 (0.767–0.910) 0.0001 9 (8–9) 16 (14–18) 0.665 (0.607–0.729) 0.0001
No 9 (8–10) 13 (11–14) 0.830 (0.768–0.897) 0.0001 10 (9–12) 21 (18–23) 0.659 (0.613–0.710) 0.0001
Chemotherapy
Yes 11 (10–11) 15 (13–17) 0.834 (0.756–0.920) 0.0003 12 (11–12) 20 (18–21) 0.662 (0.603–0.727) 0.0001
No 7 (7–8) 10 (9–11) 0.831 (0.774–0.893) 0.0001 7 (6–8) 18 (16–20) 0.650 (0.605–0.700) 0.0001
OS, overall survival; HR, hazard ratio; CI, confidence interval; AdenoCA, adenocarcinoma; BAC, bronchioloalveolar carcinoma; SqCC, squamous cell carcinoma, NOS, not
otherwise specified; AJCC, American Joint Committee on Cancer; NR, not reached.
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EGFR mutations among Asian patients and the use of oral
EGFR TKIs likely have contributed to the survival improve-
ment of Korean patients over white patients after 2002.5 In
addition, polymorphism within the EGFR may affect its
expression and led to differential outcome in NSCLC. Given
the interethnic polymorphism within intron 1 of the EGFR
gene where the polymorphism leads to lower expression of
the EGFR protein are found more commonly in Asians,18
which may lead to better survival outcome in NSCLC.19
We also reported that smoking status was an indepen-
dent prognostic factor by univariate analysis for both Korean
and whites but not a significant prognostic factor by multi-
variate analysis. In a prognostic model for gefitinib in Korean
patients, ever-smoker status was an independent unfavorable
prognostic factor. Although smoking status was incorporated
as one of the eight clinical factors of this model, it turned out
to be weakest prognostic factor for survival.20
Finally, univariate and multivariate analyses revealed
that Korean ethnicity is an independent favorable prognostic
factor for OS in NSCLC in agreement with other studies
where smoking status was taken into account.6,21 Pairwise
comparisons of OS according to individual histology indi-
cated that Korean patients had significantly improved sur-
vival than white patients. Coincidentally, the proportion of
never-smokers was significantly higher for Korean patients
than white patients irrespective of histologic type: adenocar-
cinoma (48.8% versus 16.8%; p  0.0001), squamous cell
carcinoma (11.0% versus 3.8%; p  0.0001), large cell
carcinoma (24.2% versus 6.3%; p  0.0001), BAC (60.3%
versus 24.2%; p  0.0001), and NOS/undifferentiated carci-
noma (42.8% versus 7.0%; p  0.0001). It is possible that
oral EGFR TKIs may have benefited Korean patients inde-
pendent of histologies. Indeed, in a clinical prognostic index
for erlotinib, smoking status, and ethnicity but not histology
comprised the factors that make up the prognostic index.21
Even though the proportion of never-smokers had increased
among white patients with adenocarcinoma (8.8–11.1%; p 
TABLE 7. Cox Model for Overall Survival of All Korean and
White Patients with NSCLC
Hazard
Ratio
95% Confidence
Interval p
Smoking status
Ever-smoker 1.000
Never-smoker 0.970 (0.914–1.028) 0.3023
Ethnicity
White 1.000
Korean 0.869 (0.826–0.913) 0.0001
Age 1.010 (1.009–1.012) 0.0001
Gender
Male 1.000
Female 0.836 (0.802–0.872) 0.0001
Period of diagnosis
1998–2001 1.000
2002–2005 0.897 (0.862–0.932) 0.0001
Histology
Adenocarcinoma 1.000
Bronchioloalveolar carcinoma 0.602 (0.525–0.689) 0.0001
Squamous cell carcinoma 0.994 (0.946–1.046) 0.8245
Large cell carcinoma 1.293 (1.172–1.425) 0.0001
NOS/mixed/other 1.175 (1.119–1.233) 0.0001
AJCC stagea
I 1.000
II 1.821 (1.621–2.046) 0.0001
III 2.558 (2.355–2.779) 0.0001
IV 3.803 (3.514–4.115) 0.0001
Surgery
No 1.000
Yes 0.334 (0.315–0.354) 0.0001
Radiation
No 1.000
Yes 0.951 (0.913–0.990) 0.0145
Chemotherapy
No 1.000
Yes 0.627 (0.600–0.655) 0.0001
a Unknown included but not shown.
NOS, not otherwise specified; AJCC, American Joint Committee on Cancer.
FIGURE 2. A, Kaplan-Meier survival curves of Korean patients by period of diagnosis. B, Kaplan-Meier survival curves of white
patients by period of diagnosis.
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0.0177), the proportion of never-smokers among Korean pa-
tients with adenocarcinoma had also increased (44.5–51.8%;
p  0.0009) between period 1 and period 2; the proportion of
Korean never-smokers remained higher than that of white
never-smokers in period 2 among all histologies: adenocar-
cinoma (51.8% versus 11.1%), BAC (59.3% versus 26.5%),
squamous cell carcinoma (11.6% versus 3.1%), large cell
carcinoma (25.8% versus 7.0%), and undifferentiated carci-
noma (45.0% versus 7.8%).
One of the advantages of this study is the large number
of patients with many important prognostic factors such as
age, gender, smoking status, histology, and treatment (sur-
gery, radiation, and chemotherapy) were analyzed. Another
advantage is the pathologic diagnosis of individual patient
with NSCLC was recorded using ICD-O-3 codes in both
registries providing consistency to our comparisons of
NSCLC that were geographically distant. This study further
supports that ethnicity is an independent prognostic factor in
NSCLC. Moreover, this study lends further evidence that the
introduction of oral EGFR TKIs has changed the landscape of
the treatment of NSCLC especially in Asia.
One limitation is that the Korean patient database was
generated from a single institution and may not be represen-
tative of the true composition of patients with NSCLC in
South Korea. However, close to 15% of patients with NSCLC
in South Korea are being treated at Samsung Medical Center
in Seoul. In addition, because the CCR is a population-based
database, the treatment may not be as uniform between rural
and more urban areas of California as a single institution
resulting in a lower survival. Another important limitation is
the lack of information about the amount of tobacco exposure
and whether ever-smokers were current or former smokers
because there was significant difference in the NSCLC his-
tology among Korean and white ever-smokers. Furthermore,
data on environmental tobacco smoke exposure were not
available in both registries because environment tobacco
exposure may have differential effect in the development of
lung cancer in women.10,13 Another limitation is that perfor-
mance status is not available in the datasets. Never-smokers
generally have better performance status, and in a study of
large Japanese database, performance status is an indepen-
dent prognostic factor.22 Another limitation is the proportion
of patients with EGFR mutations or the proportion of patients
exposed to EGFR TKIs could not be ascertained from CCR.
Incorporating EGFR mutations, EGFR TKIs use, and perfor-
mance status in addition to smoking status will further sup-
port the observations of this study. Finally, tumor differenti-
ation has been shown to have prognostic significance6,8;
however, this clinical variable was not included in this anal-
ysis because of unavailability from the Korean dataset.
In summary, we observed several significant differ-
ences between Korean and US white patients with NSCLC by
smoking status and gender. We also found that Korean
ethnicity is a favorable independent prognostic factor when
compared with US whites and that so far only the survival of
Korean patients had significantly improved after 2002 when
oral EGFT TKI was approved in Korea.
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